Nicotine-Binding IgG4 Antibodies for Selective Nicotine Sequestration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for aiding smoking cessation and treating nicotine toxicity, including nicotine poisoning and overdose, are inadequate, with existing antibodies lacking specificity and efficacy.
Innovation Solution
Development of nicotine-binding antibodies, particularly IgG4 variants with a S228P substitution, that exhibit high affinity and selectivity for S-(-)-nicotine, reducing plasma and brain nicotine levels, and are formulated for various administration routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibodies are used to treat nicotine toxicity, then treatment capability is provided, but specificity and efficacy are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the antibody structure through specific amino acid substitutions (e.g., S228P in IgG4) to optimize binding affinity and specificity for nicotine. This structural parameter modification enables the antibody to distinguish nicotine from similar molecules like cotinine, achieving both high specificity and efficacy in treating nicotine toxicity.
Solution Approach 2:
The patent applies local quality by focusing the antibody's binding site to specifically recognize and bind nicotine molecules with high precision. The complementarity determining regions (CDRs) are engineered to create a localized binding interface that fits nicotine's molecular structure, while the rest of the antibody molecule maintains general properties for systemic administration.
2Productivity
If antibodies with high binding affinity for nicotine are developed, then efficacy in reducing plasma nicotine levels is improved, but cross-reactivity with other molecules increases
Solution Approach 1:
The patent applies local quality by designing the antibody's binding site with precise molecular recognition features that match nicotine's unique structure. The complementarity determining regions are engineered to create a highly specific binding interface that accommodates nicotine's molecular geometry and chemical properties while rejecting structurally similar but pharmacologically different molecules like cotinine.
Solution Approach 2:
The patent applies asymmetry by creating a chiral binding site that is sensitive to the specific three-dimensional arrangement of atoms in nicotine molecules. This asymmetric recognition mechanism allows the antibody to distinguish between enantiomers and closely related molecules, maintaining high efficacy for nicotine while avoiding cross-reactivity with other chiral molecules.
3Reliability
If monoclonal antibodies against nicotine are used, then targeted treatment is achieved, but manufacturing complexity increases
Solution Approach 1:
The patent applies universality by developing a monoclonal antibody platform that can be produced through standardized recombinant DNA technology. The antibody design incorporates features that allow it to be manufactured in common expression systems like Chinese hamster ovary cells or mammalian cell lines, reducing manufacturing complexity while maintaining targeted treatment capability through consistent molecular structure.
Solution Approach 2:
The patent applies copying by using recombinant DNA technology to produce identical copies of the antibody gene sequence. This allows for consistent, scalable manufacturing of the monoclonal antibody with uniform structure and function, avoiding the complexity of isolating and characterizing each antibody molecule individually while ensuring batch-to-batch consistency in targeted treatment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively reduce nicotine levels in the body, facilitating smoking cessation and treating nicotine toxicity by sequestering nicotine, with minimal cross-reactivity to other molecules, thus providing therapeutic benefits.
Implementation Method 1
antibodies that bind nicotine... the antibody binds to nicotine... with high affinity and selectivity for S-(-)-nicotine
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3B
AI summary
Described are novel nicotine-binding antibodies and methods of using them for treating nicotine addiction and/or facilitating smoking cessation, or for treating nicotine overdose or nicotine poisoning.